Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections

Int J Antimicrob Agents. 2012 Jan;39(1):90-1. doi: 10.1016/j.ijantimicag.2011.08.007. Epub 2011 Oct 5.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Daptomycin / adverse effects
  • Daptomycin / therapeutic use*
  • Glycopeptides / adverse effects
  • Glycopeptides / therapeutic use*
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Middle Aged
  • Soft Tissue Infections / drug therapy*
  • Soft Tissue Infections / microbiology
  • Staphylococcal Skin Infections / drug therapy*
  • Staphylococcal Skin Infections / microbiology
  • Staphylococcus aureus / drug effects
  • Teicoplanin / therapeutic use
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Glycopeptides
  • Teicoplanin
  • Vancomycin
  • Daptomycin